DelveInsight launched a new report on Aneurysmal Subarachnoid Hemorrhage – Epidemiology Forecast to 2030
Some of the key facts of the report
1. The estimated incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) to be 6–8 per 100,000 annually. 2. It has been found that majority of the cases are of Grade 1&2, followed by Grade 4&5, and least are contribute by Grade 3.
” According to Delveinsight, Aneurysmal Subarachnoid Hemorrhage (aSAH) is more common in females.”
Aneurysmal Subarachnoid Hemorrhage (aSAH) is a serious condition that not just affects the brain, but multiple other organ systems as well. Despite a steady reduction of mortality from acute SAH in recent years, from over half to approximately one-third, this entity is still associated with considerable morbidity and mortality.
Aneurysmal subarachnoid hemorrhage (aSAH) is a worldwide health burden with high fatality and permanent disability rates. These aneurysms, located at the branching point of proximal intracranial arteries, are not uncommon and found in about 2% of the adult population (and even more frequently in those with a family history of aSAH or polycystic kidney disease).
Risk factors for aneurysm rupture include hypertension, smoking, heavy alcohol use, and cocaine abuse. Mortality can be as high as 50%, with 10–20% of patients dying within the first 24 h from cardiac arrhythmias or cerebral herniation.
Delayed ischemic neurologic deficit (DIND; also referred to as clinical/symptomatic vasospasm or delayed cerebral ischemia) is a serious and poorly understood complication of aSAH, occurring in 20–40% of patients.
Several grading systems are used to assess the initial clinical and radiologic features of subarachnoid hemorrhage. The two most widely used clinical scales are those of Hunt and Hess and the World Federation of Neurological Surgeons. The latter is currently preferred since it is based on the sum score of the Glasgow Coma Scale (a very reliable method for evaluating the level of consciousness) and the presence of focal neurologic signs.
The incidence of aSAH has been shown to be associated with numerous nonmodifiable (age, gender, ethnicity, family history, aneurysm location, and size) and modifiable (hypertension, body mass index, tobacco, and illicit drug use) risk factors. Although early repair of ruptured aneurysms and aggressive postoperative management has improved the overall outcomes.
The treatment of aneurysmal subarachnoid hemorrhage (aSAH) was subject to fundamental changes in the last two decades. The introduction of endovascular coiling, beside the wellestablished method of neurosurgical clipping, extended the treatment options in aSAH. With the evolution of endovascular procedures, the availability of coiling became more widespread.
Scope of the Report
Request for sample pages : https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-epidemiology-forecast
Report Highlights
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
Reasons to buy
Key Assessments
Related Reports:
Aneurysmal Subarachnoid Hemorrhage (aSAH) – Pipeline Insights, 2020
The Aneurysmal Subarachnoid Hemorrhage (aSAH) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Aneurysmal Subarachnoid Hemorrhage (aSAH) across the complete product development cycle, including all clinical and nonclinical stages.
Aneurysmal Subarachnoid Hemorrhage (SAH) – Market Insights, Epidemiology, and Market Forecast-2030
The Aneurysmal Subarachnoid Hemorrhage (SAH) market report provides current treatment practices, emerging drugs, Aneurysmal Subarachnoid Hemorrhage (SAH) market share of the individual therapies, current and forecasted Aneurysmal Subarachnoid Hemorrhage (SAH) market Size from 2017 to 2030 segmented by seven major markets.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/